Nitric Oxide–Dependent Activation of P53 Suppresses Bleomycin-Induced Apoptosis in the Lung

Chronic inflammation leading to pulmonary fibrosis develops in response to environmental pollutants, radiotherapy, or certain cancer chemotherapeutic agents. We speculated that lung injury might be mediated by p53, a proapoptotic transcription factor widely implicated in the response of cells to DNA damage. Intratracheal administration of bleomycin led to caspase-mediated DNA fragmentation characteristic of apoptosis. The effects of bleomycin were associated with translocation of p53 from the cytosol to the nucleus only in alveolar macrophages that had been exposed to the drug in vivo, suggesting that the lung microenvironment regulated p53 activation. Experiments with a thiol antioxidant (N-acetylcysteine) in vivo and nitric oxide (NO) donors in vitro confirmed that reactive oxygen species were required for p53 activation. A specific role for NO was demonstrated in experiments with inducible nitric oxide synthase (iNOS)−/− macrophages, which failed to demonstrate nuclear p53 localization after in vivo bleomycin exposure. Strikingly, rates of bleomycin-induced apoptosis were at least twofold higher in p53−/− C57BL/6 mice compared with heterozygous or wild-type littermates. Similarly, levels of apoptosis were also twofold higher in the lungs of iNOS−/− mice than were observed in wild-type controls. Consistent with a role for apoptosis in chronic lung injury, levels of bleomycin-induced inflammation were substantially higher in iNOS−/− and p53−/− mice compared with wild-type controls. Together, our results demonstrate that iNOS and p53 mediate a novel apoptosis-suppressing pathway in the lung.

[1]  M. Tang,et al.  Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. , 2000, Journal of the National Cancer Institute.

[2]  P. Hainaut,et al.  Nitric oxide nitrates tyrosine residues of tumor-suppressor p53 protein in MCF-7 cells. , 2000, Biochemical and biophysical research communications.

[3]  B. Brüne,et al.  p53 accumulation in apoptotic macrophages is an energy demanding process that precedes cytochrome c release in response to nitric oxide , 1999, Oncogene.

[4]  K. Okudela,et al.  The role of p53 in bleomycin-induced DNA damage in the lung. A comparative study with the small intestine. , 1999, The American journal of pathology.

[5]  M. Scheffner,et al.  Activation of the Cell Death Program by Nitric Oxide Involves Inhibition of the Proteasome* , 1999, The Journal of Biological Chemistry.

[6]  K. Miyazono,et al.  Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation , 1999, The EMBO journal.

[7]  A. Wyllie,et al.  P53-dependent and -independent links between DNA-damage, apoptosis and mutation frequency in ES cells , 1999, Oncogene.

[8]  M. Asada,et al.  p21Cip1/WAF1 is important for differentiation and survival of U937 cells , 1998, Leukemia.

[9]  D. McConkey,et al.  Biochemical determinants of apoptosis and necrosis. , 1998, Toxicology letters.

[10]  D. Lane,et al.  Cancer: Awakening angels , 1998, Nature.

[11]  A. Boobis,et al.  Pulmonary fibrosis correlates with duration of tissue neutrophil activation. , 1998, American journal of respiratory and critical care medicine.

[12]  D. Harrison,et al.  p53‐independent DNA repair and cell cycle arrest in embryonic stem cells , 1998, FEBS letters.

[13]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[14]  R. Hynes,et al.  Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. , 1998, The Journal of clinical investigation.

[15]  T. McDonnell,et al.  Bcl-2 inhibits p53 nuclear import following DNA damage , 1997, Oncogene.

[16]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[17]  M. Greaves,et al.  Absence of p53 permits propagation of mutant cells following genotoxic damage , 1997, Oncogene.

[18]  C. Nathan,et al.  Nitric oxide and macrophage function. , 1997, Annual review of immunology.

[19]  K. Kuwano,et al.  Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. , 1997, American journal of respiratory cell and molecular biology.

[20]  C. Vogelmeier,et al.  Oxidant-protease interaction in the lung. Prospects for antioxidant therapy. , 1996, Chest.

[21]  R. Hamilton,et al.  Asbestos induces apoptosis in human alveolar macrophages. , 1996, The American journal of physiology.

[22]  R. Iyer,et al.  Silica-induced apoptosis mediated via scavenger receptor in human alveolar macrophages. , 1996, Toxicology and applied pharmacology.

[23]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[24]  C. Haslett,et al.  In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. , 1996, Journal of immunology.

[25]  J. Piette,et al.  Anti‐apoptotic activity of low levels of wild‐type p53. , 1996, The EMBO journal.

[26]  J. Lotem,et al.  Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Kuwano,et al.  P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. , 1996, American journal of respiratory and critical care medicine.

[28]  J. Savill,et al.  What role does apoptosis play in progression of renal disease? , 1996, Current opinion in nephrology and hypertension.

[29]  C. Harris,et al.  Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Hamilton,et al.  Bleomycin induces apoptosis in human alveolar macrophages. , 1995, The American journal of physiology.

[31]  T. Taniguchi,et al.  An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes , 1995, Nature.

[32]  C. Nathan,et al.  Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase , 1995, Cell.

[33]  J. Ahearn,et al.  Novel packages of viral and self-antigens are generated during apoptosis , 1995, The Journal of experimental medicine.

[34]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[35]  C J Kemp,et al.  The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. , 1994, Cancer research.

[36]  P. Baeuerle,et al.  Function and activation of NF-kappa B in the immune system. , 1994, Annual review of immunology.

[37]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[38]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[39]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[40]  D. Lane A death in the life of p53 , 1993, Nature.

[41]  C. Haslett,et al.  Phagocyte recognition of cells undergoing apoptosis. , 1993, Immunology today.

[42]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[43]  J Savill,et al.  Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. , 1992, The Journal of clinical investigation.

[44]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[45]  D. Petering,et al.  Properties of redox-inactivated bleomycins. In vitro DNA damage and inhibition of Ehrlich cell proliferation. , 1992, Biochemical pharmacology.

[46]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[47]  R. Crystal Oxidants and respiratory tract epithelial injury: pathogenesis and strategies for therapeutic intervention. , 1991, The American journal of medicine.

[48]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[49]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[50]  D. Sem,et al.  Intracellular DNA strand scission and growth inhibition of Ehrlich ascites tumor cells by bleomycins. , 1990, Cancer research.

[51]  D. White,et al.  Bleomycin-induced pulmonary toxicity. , 1990, Clinics in chest medicine.

[52]  S. Orrenius,et al.  Calcium-dependent killing of immature thymocytes by stimulation via the CD3/T cell receptor complex. , 1989, Journal of immunology.

[53]  D. Hyde,et al.  Effects of repeated administration of N-acetyl-L-cysteine on sulfhydryl levels of different tissues and bleomycin-induced lung fibrosis in hamsters. , 1988, The Journal of laboratory and clinical medicine.

[54]  S. Hecht DNA strand scission by activated bleomycin group antibiotics. , 1986, Federation proceedings.

[55]  R. Crystal,et al.  Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. , 1984, The New England journal of medicine.

[56]  R. Crystal,et al.  Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts). , 1984, The New England journal of medicine.

[57]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[58]  K. Pennline,et al.  Alveolar macrophage--induced suppression of the immune response. , 1979, Advances in experimental medicine and biology.

[59]  B. Starcher,et al.  Increased elastin and collagen content in the lungs of hamsters receiving an intratracheal injection of bleomycin. , 2015, The American review of respiratory disease.